Fares Auda, Borrmann Dieter, Ivester Julius R
St. Willibrord- Spital Emmerich-Rees Hospital, Acute Geriatrics Medicine and Rehabilitation, Emmerich am Rhein/ Germany.
Department of Anaesthesia and Pain Management, Roper Hospital, Charleston, SC, USA.
J Infect Prev. 2021 Jul;22(4):177-180. doi: 10.1177/1757177420982049. Epub 2021 Jan 12.
Novel coronavirus disease 2019 (COVID-19) is a highly infectious, rapidly spreading viral disease and has emerged as a public health emergency of international concern. As of this time, there are no specific antiviral therapies available for the treatment of COVID-19. However, it is possible that some existing drugs, usually used for other conditions, may have some benefits. Statins have been widely reported to exert antiviral activity against many enveloped viruses by inhibiting the cholesterol biosynthesis pathway. Cholesterol likewise contributes to the coronavirus's life cycle, including viral entry, fusion and budding. In addition, statins have been ascribed beneficial anti-inflammatory, immunomodulatory effects and promote haemodynamic stability. Therefore, statins, which are cholesterol-lowering drugs with anti-inflammatory, immunomodulatory and antiviral properties, may play a role in SARS-CoV-2 therapy. The aim of the present minireview was to delineate the potential beneficial therapeutic effects of statins in treating SARS-CoV-2 infections. Nevertheless, large, randomised trials are needed to confirm the beneficial effects and safety profile of the statins in patients with SARS-CoV-2.
2019年新型冠状病毒病（COVID-19）是一种传染性极强、传播迅速的病毒性疾病，已成为国际关注的突发公共卫生事件。截至目前，尚无用于治疗COVID-19的特异性抗病毒疗法。然而，一些通常用于治疗其他疾病的现有药物可能具有一定益处。他汀类药物已被广泛报道可通过抑制胆固醇生物合成途径对多种包膜病毒发挥抗病毒活性。胆固醇同样参与冠状病毒的生命周期，包括病毒进入、融合和出芽。此外，他汀类药物具有有益的抗炎、免疫调节作用，并能促进血流动力学稳定。因此，他汀类药物作为具有抗炎、免疫调节和抗病毒特性的降胆固醇药物，可能在SARS-CoV-2治疗中发挥作用。本综述的目的是阐述他汀类药物在治疗SARS-CoV-2感染方面潜在的有益治疗作用。然而，需要进行大规模随机试验来证实他汀类药物对SARS-CoV-2患者的有益效果和安全性。
